China · Delayed Price · Currency is CNY Luyan Pharma Statistics
Total Valuation
Luyan Pharma has a market cap or net worth of CNY 3.11 billion. The enterprise value is 7.60 billion.
| Market Cap | 3.11B |
| Enterprise Value | 7.60B |
Important Dates
The next estimated earnings date is Tuesday, October 21, 2025.
| Earnings Date | Oct 21, 2025 |
| Ex-Dividend Date | Jul 10, 2025 |
Share Statistics
Luyan Pharma has 388.52 million shares outstanding. The number of shares has decreased by -0.22% in one year.
| Current Share Class | 388.52M |
| Shares Outstanding | 388.52M |
| Shares Change (YoY) | -0.22% |
| Shares Change (QoQ) | -5.01% |
| Owned by Insiders (%) | 3.68% |
| Owned by Institutions (%) | 3.01% |
| Float | 231.73M |
Valuation Ratios
The trailing PE ratio is 10.00.
| PE Ratio | 10.00 |
| Forward PE | n/a |
| PS Ratio | 0.15 |
| PB Ratio | 0.97 |
| P/TBV Ratio | 1.23 |
| P/FCF Ratio | 16.53 |
| P/OCF Ratio | 6.31 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.96, with an EV/FCF ratio of 40.41.
| EV / Earnings | 24.52 |
| EV / Sales | 0.37 |
| EV / EBITDA | 9.96 |
| EV / EBIT | 11.99 |
| EV / FCF | 40.41 |
Financial Position
The company has a current ratio of 1.13, with a Debt / Equity ratio of 1.55.
| Current Ratio | 1.13 |
| Quick Ratio | 0.79 |
| Debt / Equity | 1.55 |
| Debt / EBITDA | 6.52 |
| Debt / FCF | 26.45 |
| Interest Coverage | 3.19 |
Financial Efficiency
Return on equity (ROE) is 9.76% and return on invested capital (ROIC) is 4.89%.
| Return on Equity (ROE) | 9.76% |
| Return on Assets (ROA) | 3.21% |
| Return on Invested Capital (ROIC) | 4.89% |
| Return on Capital Employed (ROCE) | 16.00% |
| Revenue Per Employee | 3.67M |
| Profits Per Employee | 55,302 |
| Employee Count | 5,602 |
| Asset Turnover | 1.67 |
| Inventory Turnover | 7.60 |
Taxes
In the past 12 months, Luyan Pharma has paid 101.07 million in taxes.
| Income Tax | 101.07M |
| Effective Tax Rate | 24.57% |
Stock Price Statistics
The stock price has increased by +13.31% in the last 52 weeks. The beta is 0.35, so Luyan Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | +13.31% |
| 50-Day Moving Average | 8.57 |
| 200-Day Moving Average | 8.39 |
| Relative Strength Index (RSI) | 33.29 |
| Average Volume (20 Days) | 5,554,637 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Luyan Pharma had revenue of CNY 20.56 billion and earned 309.80 million in profits. Earnings per share was 0.80.
| Revenue | 20.56B |
| Gross Profit | 1.49B |
| Operating Income | 633.55M |
| Pretax Income | 411.45M |
| Net Income | 309.80M |
| EBITDA | 700.53M |
| EBIT | 633.55M |
| Earnings Per Share (EPS) | 0.80 |
Balance Sheet
The company has 513.85 million in cash and 4.97 billion in debt, giving a net cash position of -4.46 billion or -11.48 per share.
| Cash & Cash Equivalents | 513.85M |
| Total Debt | 4.97B |
| Net Cash | -4.46B |
| Net Cash Per Share | -11.48 |
| Equity (Book Value) | 3.21B |
| Book Value Per Share | 8.18 |
| Working Capital | 1.15B |
Cash Flow
In the last 12 months, operating cash flow was 492.39 million and capital expenditures -304.40 million, giving a free cash flow of 187.99 million.
| Operating Cash Flow | 492.39M |
| Capital Expenditures | -304.40M |
| Free Cash Flow | 187.99M |
| FCF Per Share | 0.48 |
Margins
Gross margin is 7.24%, with operating and profit margins of 3.08% and 1.51%.
| Gross Margin | 7.24% |
| Operating Margin | 3.08% |
| Pretax Margin | 2.00% |
| Profit Margin | 1.51% |
| EBITDA Margin | 3.41% |
| EBIT Margin | 3.08% |
| FCF Margin | 0.91% |
Dividends & Yields
This stock pays an annual dividend of 0.35, which amounts to a dividend yield of 4.33%.
| Dividend Per Share | 0.35 |
| Dividend Yield | 4.33% |
| Dividend Growth (YoY) | 16.67% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 103.08% |
| Buyback Yield | 0.22% |
| Shareholder Yield | 4.60% |
| Earnings Yield | 9.97% |
| FCF Yield | 6.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 29, 2019. It was a forward split with a ratio of 1.7.
| Last Split Date | May 29, 2019 |
| Split Type | Forward |
| Split Ratio | 1.7 |
Scores
Luyan Pharma has an Altman Z-Score of 2.34 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.34 |
| Piotroski F-Score | 5 |